


Solventum at a glance

At Solventum, we enable better, smarter, safer healthcare to improve lives. Across our businesses — Medical Surgical (MedSurg), Dental Solutions and Health Information Systems (HIS) — we have strong positions in diverse and growing markets, trusted and recognized brands and global commercial scale and reach.

 **70+**
year history of innovation

 **20,000+**
employees

 **6,500+**
patents issued

 **100,000+**
customers and channel partners globally in 90+ countries



Business segments at a glance

	Total company sales ¹	Growth drivers	Q4 2025 highlights
<p>MedSurg</p> <p>Provides advanced wound care, infection prevention and surgical solutions intended to accelerate healing, prevent complications and lower the total cost of care globally.</p> 	62%	<ul style="list-style-type: none"> Negative pressure wound therapy IV site management Sterilization assurance 	<ul style="list-style-type: none"> Specialized commercial organization delivering results Negative pressure wound therapy growth Strong brand equity and momentum from recent product launches in infection prevention & surgical solutions
<p>Dental Solutions</p> <p>Offers the most comprehensive dental solutions for patients to enjoy healthy, beautiful smiles through game-changing innovation</p> 	17%	<ul style="list-style-type: none"> Core restoratives 	<ul style="list-style-type: none"> Strong existing brands Recent product launches and sales channel specialization Backorder improvements
<p>Health Information Systems</p> <p>Delivers innovative software solutions and services, designed to eliminate revenue cycle waste, create more time for patient care and support the shift to value-based care</p> 	17%	<ul style="list-style-type: none"> Revenue cycle management 	<ul style="list-style-type: none"> Strong growth in revenue cycle management Continued adoption and international expansion of 360 Encompass™ Progress in autonomous coding with customers and partners

1. Calculated as a % of Q4 2025 net sales.

Q4 financial highlights *

Sales

\$2.0B (3.7)% total sales growth
+3.5% organic sales growth

Diluted GAAP EPS

\$0.36

Solid foundation to continue momentum in 2026

Operating cash flow

\$96M

Diluted adjusted EPS

\$1.57

* See non-GAAP financial measures and reconciliation schedules included in our earnings release dated February 26, 2026, which can be found on our investor relations website.

Segment highlights

Strong progress propelled by growth drivers

Business segment

Reported sales growth

Organic sales growth

MedSurg

+5.2%

+3.2%

Dental Solutions

+8.6%

+5.9%

Health Information Systems

+3.7%

+3.2%



2026 guidance

Continued growth and margin expansion in 2026

Organic sales growth

+2.0% to +3.0%

+3.0% to +4.0% excluding ~100 bps of SKU exit impact

Adjusted diluted EPS

\$6.40 to \$6.60

Free cash flow

~\$200M



Forward looking statements

This communication and other materials Solventum has filed or will file with the U.S. Securities & Exchange Commission ("SEC") (and oral communications that Solventum may make) contain or incorporate by reference statements that relate to future events and expectations and, as such, constitute forward-looking statements that involve risk and uncertainties. Forward-looking statements include those containing such words as "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "guidance," "intends," "may," "outlook," "plans," "projects," "seeks," "sees," "should," "targets," "will," "would" or other words of similar meaning. All statements that reflect Solventum's expectations, assumptions or projections about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, forecasts relating to discussions of future operations and financial performance (including volume growth, pricing, sales and earnings per share growth and cash flows) and statements regarding Solventum's strategy for growth, future product development, regulatory clearances and approvals, competitive position and expenditures. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and changes in circumstances. Actual future results and trends may differ materially from historical results or those reflected in any such forward-looking statements depending on a variety of factors. Solventum assumes no obligation to update or revise such statements, whether as a result of new information, future events or otherwise, except as required by applicable law. A further description of these factors is located under "Cautionary Note Regarding Forward-Looking Statements" and "Risk Factors" in Solventum's periodic reports on file with the SEC. Solventum assumes no obligation to update any forward-looking statements discussed herein as a result of new information or future events or developments.

Non-GAAP financial measures

In addition to reporting financial results in accordance with U.S. GAAP, Solventum also provides non-GAAP measures that we use, and plan to continue using, when monitoring and evaluating operating performance and measuring cash available to invest in our business. The adjusted measures are not in accordance with, nor are they a substitute for GAAP measures. These non-GAAP financial measures are supplemental measures of our performance and our liquidity that we believe help investors understand our underlying business performance and Solventum uses these measures as an indication of the strength of Solventum and its ability to generate cash. Refer to the reconciliation schedules included in our Earnings Release dated February 26, 2026, which can be found on our investor relations website, for descriptions and reconciliations of financial measures such as organic sales growth, adjusted operating income and adjusted operating income margin, adjusted earnings per share, and free cash flow. Solventum calculates forward-looking non-GAAP financial measures, including organic sales growth, adjusted operating income, adjusted operating income margin, adjusted effective tax rate, adjusted earnings per share and free cash flow based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. Solventum does not provide reconciliations of these forward-looking non-GAAP financial measures to the respective GAAP metrics as it is unable to predict with reasonable certainty and without unreasonable effort certain items such as the impact of changes in currency exchange rates, impacts associated with business acquisitions or divestitures and the timing and magnitude of restructuring activities, among other items. The timing and amounts of these items are uncertain and could have a material impact on Solventum's results in accordance with GAAP.

The Q4 2025 financial statements and financial information, including reconciliations of non-GAAP financial measures, are available on Solventum's website: investors.solventum.com.

